Report of Foreign Issuer (6-k)

Date : 11/07/2019 @ 10:12PM
Source : Edgar (US Regulatory)
Stock : Affimed NV (AFMD)
Quote : 2.3  -0.03 (-1.29%) @ 5:17PM

Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November, 2019

Commission File Number: 001-36619

 

 

Affimed N.V.

 

 

Im Neuenheimer Feld 582,

69120 Heidelberg,

Germany

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F              Form 40-F  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  

 

 

 


Affimed N.V. (“Affimed” or the “Company”) today issued three press releases. Copies of each of the Company’s press releases are filed as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 to this Report on Form 6-K, and are incorporated herein by reference.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Heidelberg, Germany,

November 7, 2019.

 

AFFIMED N.V.
By:  

/s/ Adi Hoess

  Name: Adi Hoess
  Title: Chief Executive Officer
By:  

/s/ Florian Fischer

  Name: Florian Fischer
  Title: Chief Financial Officer


EXHIBIT INDEX

 

Exhibit

  

Description of Exhibit

99.1    Affimed N.V. Press Release “Affimed Announces Proposed Public Offering of Common Shares,” dated November 7, 2019
99.2    Affimed N.V. Press Release “Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech” dated November 7, 2019
99.3    Affimed N.V. Press Release “Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers,” dated November 7, 2019

Affimed NV (NASDAQ:AFMD)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Affimed NV Charts.

Affimed NV (NASDAQ:AFMD)
Intraday Stock Chart

Today : Thursday 5 December 2019

Click Here for more Affimed NV Charts.

Latest AFMD Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.